Clinical Trial Update: An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Gevokizumab for active ulcers in Pyoderma gangrenosum was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyoderma Gangrenosum

Drugs mentioned

• Gevokizumab (gevokizumab)

Snippet

Sponsor: XOMA (US) LLC | Conditions: Pyoderma Gangrenosum | Phase 3 | Status: TERMINATED